Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of PF-06439535 (Zirabev) vs Bevacizumab-EU in Healthy Chinese Males
NCT04126044Phase 1Withdrawn
- Sponsor
- Pfizer
- Start
- Jan 2021
- Primary completion
- Jul 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of bevacizumab-bvzr in metastatic colorectal cancer (mCRC), non-small cell lung cancer (NSCLC), glioblastoma (GBM) and 2 more (2 arms), sponsored by Pfizer. Primary endpoint: Area under the serum concentration-time profile from time 0 to last time point with quantifiable concentration. Planned start Jan 2021; status: withdrawn.
02
Drugs
bevacizumab-bvzr
03
Conditions
metastatic colorectal cancer (mCRC)non-small cell lung cancer (NSCLC)glioblastoma (GBM)renal cell carcinoma (RCC)Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT04126044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04126044.